Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors that have spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable), and have changes in a gene called human epidermal growth factor receptor 2 (HER2). Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them. Adding neratinib to trastuzumab deruxtecan may be able to shrink cancer with a change in the HER2 gene.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór stały, który się rozprzestrzeniał (przerzuty) lub nie można go usunąć operacyjnie
- •Nowotwór musi mieć dodatni HER2 (określony testami laboratoryjnymi)
- •Leczenie w tym badaniu musi być uznane za najlepszą opcję dalszego leczenia
- •W części badania dotyczącej trzustki: potwierdzony rak trzustki (adenokarcynoma) z dodatnim HER2
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (18)
City of Hope Comprehensive Cancer Center
Duarte, United States
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, United States
City of Hope at Irvine Lennar
Irvine, United States
City of Hope Antelope Valley
Lancaster, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, United States
University of California Davis Comprehensive Cancer Center
Sacramento, United States
City of Hope South Pasadena
South Pasadena, United States
City of Hope Upland
Upland, United States
UF Health Cancer Institute - Gainesville
Gainesville, United States
Northwestern University
Chicago, United States
University of Kentucky/Markey Cancer Center
Lexington, United States
Dana-Farber Cancer Institute
Boston, United States
Washington University School of Medicine
St Louis, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, United States
UT MD Anderson Cancer Center
Houston, United States
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, United States
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, United States
Trial contact
Site Public Contact
Dani R. Castillo
PRINCIPAL_INVESTIGATOR
Site Public Contact
Farshid Dayyani
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Mili Arora
PRINCIPAL_INVESTIGATOR
Site Public Contact
Thomas J. George
PRINCIPAL_INVESTIGATOR
Site Public Contact
Aparna Kalyan
PRINCIPAL_INVESTIGATOR
Site Public Contact
Reema A. Patel
PRINCIPAL_INVESTIGATOR
Site Public Contact
Haeseong Park
PRINCIPAL_INVESTIGATOR
Site Public Contact
Andrew Davis
PRINCIPAL_INVESTIGATOR
Site Public Contact
Floor Backes
PRINCIPAL_INVESTIGATOR
Site Public Contact
Sarah E. Taylor
PRINCIPAL_INVESTIGATOR
Site Public Contact
Ecaterina E. Ileana Dumbrava
PRINCIPAL_INVESTIGATOR
Site Public Contact
Nataliya V. Uboha
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.